Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Cash Flows

v2.4.1.9
Consolidated Statements of Cash Flows (USD $)
In Thousands, unless otherwise specified
12 Months Ended
Dec. 31, 2014
Dec. 31, 2013
Dec. 31, 2012
Cash flows from operating activities:      
Net loss $ (21,584)us-gaap_NetIncomeLoss $ (28,415)us-gaap_NetIncomeLoss $ (71,135)us-gaap_NetIncomeLoss
Adjustments to reconcile net loss to net cash used in operating activities:      
Depreciation and amortization 1,309us-gaap_DepreciationAndAmortization 1,506us-gaap_DepreciationAndAmortization 1,008us-gaap_DepreciationAndAmortization
Stock-based compensation expense 5,488us-gaap_ShareBasedCompensation 4,922us-gaap_ShareBasedCompensation 3,010us-gaap_ShareBasedCompensation
Change in common stock warrant value (9,344)us-gaap_GainLossOnDerivativeInstrumentsNetPretax 2,325us-gaap_GainLossOnDerivativeInstrumentsNetPretax 51,216us-gaap_GainLossOnDerivativeInstrumentsNetPretax
(Gain) loss on sale of investments, property and equipment (3)us-gaap_GainLossOnDispositionOfAssets1 (5)us-gaap_GainLossOnDispositionOfAssets1  
Changes in operating assets and liabilities:      
Collaboration receivable 10,846us-gaap_IncreaseDecreaseInOtherReceivables (2,459)us-gaap_IncreaseDecreaseInOtherReceivables (15,635)us-gaap_IncreaseDecreaseInOtherReceivables
Prepaid expenses and other current assets 1,314us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets (1,079)us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets (623)us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
Accounts payable 385us-gaap_IncreaseDecreaseInAccountsPayable 781us-gaap_IncreaseDecreaseInAccountsPayable (1,481)us-gaap_IncreaseDecreaseInAccountsPayable
Accrued clinical and development expenses (1,446)thld_IncreaseDecreaseInAccruedClinicalAndDevelopmentLiabilities 1,694thld_IncreaseDecreaseInAccruedClinicalAndDevelopmentLiabilities 1,285thld_IncreaseDecreaseInAccruedClinicalAndDevelopmentLiabilities
Accrued liabilities 19us-gaap_IncreaseDecreaseInAccruedLiabilities 904us-gaap_IncreaseDecreaseInAccruedLiabilities 520us-gaap_IncreaseDecreaseInAccruedLiabilities
Deferred rent 3us-gaap_IncreaseDecreaseInDeferredCharges (28)us-gaap_IncreaseDecreaseInDeferredCharges 115us-gaap_IncreaseDecreaseInDeferredCharges
Deferred revenue (14,722)us-gaap_IncreaseDecreaseInDeferredRevenue 30,005us-gaap_IncreaseDecreaseInDeferredRevenue 61,633us-gaap_IncreaseDecreaseInDeferredRevenue
Net cash provided by (used in) operating activities (27,735)us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations 10,151us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations 29,913us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
Cash flows from investing activities:      
Acquisition of property and equipment (224)us-gaap_PaymentsToAcquirePropertyPlantAndEquipment (158)us-gaap_PaymentsToAcquirePropertyPlantAndEquipment (482)us-gaap_PaymentsToAcquirePropertyPlantAndEquipment
Acquisition of marketable securities (44,911)us-gaap_PaymentsToAcquireAvailableForSaleSecurities (101,968)us-gaap_PaymentsToAcquireAvailableForSaleSecurities (93,745)us-gaap_PaymentsToAcquireAvailableForSaleSecurities
Proceeds from sales of marketable securities 14,584us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities 5,338us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities 14,266us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities
Proceeds from maturities of marketable securities 53,878us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities 80,495us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities 33,285us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
Net cash provided by (used in) investing activities 23,327us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations (16,293)us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations (46,676)us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
Cash flows from financing activities:      
Proceeds from issuance of common stock and warrants, net of offering expenses 5,520us-gaap_ProceedsFromIssuanceOfCommonStock 2,392us-gaap_ProceedsFromIssuanceOfCommonStock 21,910us-gaap_ProceedsFromIssuanceOfCommonStock
Net cash provided by financing activities 5,520us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations 2,392us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations 21,910us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
Net increase (decrease) in cash and cash equivalents 1,112us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease (3,750)us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease 5,147us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease
Cash and cash equivalents, beginning of period 7,279us-gaap_CashAndCashEquivalentsAtCarryingValue 11,029us-gaap_CashAndCashEquivalentsAtCarryingValue 5,882us-gaap_CashAndCashEquivalentsAtCarryingValue
Cash and cash equivalents, end of period 8,391us-gaap_CashAndCashEquivalentsAtCarryingValue 7,279us-gaap_CashAndCashEquivalentsAtCarryingValue 11,029us-gaap_CashAndCashEquivalentsAtCarryingValue
Non-cash investing and financing activities:      
Change in unrealized gain (loss) in marketable securities $ (41)us-gaap_AvailableforsaleSecuritiesGrossUnrealizedGainLoss1 $ 17us-gaap_AvailableforsaleSecuritiesGrossUnrealizedGainLoss1 $ 12us-gaap_AvailableforsaleSecuritiesGrossUnrealizedGainLoss1